Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Opnåelse af LLDAS5 hos patienter med systemisk lupus erythematosus behandlet med anifrolumab. (DAHLIA)

18. september 2026 opdateret af: AstraZeneca

DAHLIA: Opnåelse af lavt niveau for sygdomsaktivitet med en dosis af kortikosteroider mindre end eller lig med 5 mg (LLDAS5): et real-life studie med anifrolumab på patienter med systemisk lupus erythematosus i Italien

This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Detaljeret beskrivelse

DAHLIA study aims to expand real-world evidence on anifrolumab role in clinical practice, specifically evaluating its effectiveness in achieving and maintenance of LLDAS with a dose of corticosteroids less than or equal to 5 mg/day (LLDAS5). Moreover it will provide data on corticosteroid tapering strategies. Additionally, will be also evaluated the Definitions Of Remission In SLE (DORIS) remission during the study period, as well as the depressive symptoms of these patients.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

218

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Ancona, Italien, 60126
        • Rekruttering
        • AOU Ospedali Riuniti di Ancona - Presidio Torrette
      • Bari, Italien, 70124
        • Trukket tilbage
        • Azienda Ospedaliero-Universitaria Policlinico di Bari
      • Brescia, Italien, 25123
        • Rekruttering
        • ASST Spedali Civili di Brescia
      • Florence, Italien, 50134
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Careggi
      • Milan, Italien
        • Ikke rekrutterer endnu
        • IRCCS Ospedale San Raffaele
      • Milan, Italien, 20122
        • Rekruttering
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
      • Modena, Italien, 41124
        • Ikke rekrutterer endnu
        • Policlinico di Modena - AOU di Modena
      • Naples, Italien
        • Ikke rekrutterer endnu
        • Azienda Ospedaliera Universitaria "Luigi Vanvitelli"
      • Padova, Italien, 35128
        • Ikke rekrutterer endnu
        • Azienda Ospedaliera di Padova
      • Palermo, Italien, 90127
        • Rekruttering
        • Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
      • Pavia, Italien, 27100
        • Rekruttering
        • Fondazione IRCCS Policlinico San Matteo
      • Pisa, Italien, 56126
        • Ikke rekrutterer endnu
        • Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara
      • Roma, Italien, 00133
        • Ikke rekrutterer endnu
        • Policlinico Tor Vergata
      • Roma, Italien, 00161
        • Rekruttering
        • Policlinico Umberto I - Sapienza Università di Roma
      • Torino, Italien, 10128
        • Ikke rekrutterer endnu
        • Azienda Ospedaliera Ordine Mauriziano Umberto I
      • Trieste, Italien, 34128
        • Rekruttering
        • Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI) - Ospedale di Cattinara
      • Udine, Italien, 33100
        • Rekruttering
        • ASU Friuli Centrale - Ospedale Santa Maria della Misericordia di Udine
      • Verona, Italien, 37134
        • Rekruttering
        • AOUI Verona - Ospedale Borgo Roma
    • CA
      • Monserrato, CA, Italien, 09032
        • Rekruttering
        • Azienda Ospedaliero-Universitaria di Cagliari Presidio di Monserrato
    • Ferrara
      • Cona, Ferrara, Italien, 44124
        • Rekruttering
        • Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna
    • Foggia
      • San Giovanni Rotondo, Foggia, Italien
        • Rekruttering
        • IRCCS Casa Sollievo della Sofferenza
    • Milano
      • Rozzano, Milano, Italien, 20089
        • Rekruttering
        • IRCCS Humanitas Research Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adult patients with Systemic Lupus Erythematous (SLE) according to 2019 EULAR/ACR classification criteria, treated with anifrolumab as per clinical practices.

Beskrivelse

Inclusion Criteria:

  • Provided informed consent to participate in the study;
  • Aged 18 years or older;
  • Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
  • Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;

Exclusion Criteria:

  • Patients who are at LLDAS5 at the time of study entry;
  • Previous exposure to anifrolumab;
  • Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy [mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
  • Currently participating in any interventional clinical trial with an investigational product;
  • Inability to understand and sign the informed consent and to fill in patient questionnaires

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number and percentage of patients achieving LLDAS5
Tidsramme: 52 weeks

proportion of patients with LLDAS5 at 52 weeks, defined as:

LLDAS5 is defined as follows:

  • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≤ 4, with no activity in major organ systems and no haemolytic anaemia or gastrointestinal activity;
  • No new lupus disease activity compared with previous assessment as defined per protocol;
  • Physician's Global Assessment (PGA) ≤1;
  • Current prednisone (-equivalent) dose ≤ 5mg/day;
  • Well-tolerated standard maintenance dose of immunosuppressive drugs and biologics if any.
52 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number and percentage of patients reaching LLDAS5 at each time point
Tidsramme: week 24, 76 and 104

Proportion of patients with LLDAS5, according the following definition:

LLDAS5 is defined as follows:

  • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≤ 4, with no activity in major organ systems and no haemolytic anaemia or gastrointestinal activity;
  • No new lupus disease activity compared with previous assessment as defined per protocol;
  • Physician's Global Assessment (PGA) ≤1;
  • Current prednisone (-equivalent) dose ≤ 5mg/day;
  • Well-tolerated standard maintenance dose of immunosuppressive drugs and biologics if any.
week 24, 76 and 104
Number and percentage of patients achieving a GCS (Glucocorticosterioids) dose reduction
Tidsramme: week 4, 12, 24, 52, 76, 104 vs baseline

Number and percentage of patients achieving a GCS dose reduction (to ≤ 5 mg/day; to 0 mg/day) at different timepoints (T1, T2, T3, T4, T5, T6) compared to T0

week 4, 12, 24, 52, 76, 104 vs baseline
Median (range) cumulative dose of GCS
Tidsramme: from week 0 to week 24; from week 24 to week 52; from week 52 to week 76; from week 76 to week 104

Median cumulative dose of GCS calculated at each 6 month period following T0

from week 0 to week 24; from week 24 to week 52; from week 52 to week 76; from week 76 to week 104
Mean(SD) change in tender and swollen joint count
Tidsramme: week 4, 12, 24, 52, 76 and 104 vs week 0

Mean change in tender and swollen joint count using Disease Activity Score 28 (DAS28) map at different timepoints compared to baseline (w0). DAS28 ranges from 0 (no-activity) to 10 (high disease activity)

week 4, 12, 24, 52, 76 and 104 vs week 0
mean (SD) change in Power Doppler (PD) Signal Total score
Tidsramme: week 4, 12, 24, 52, 76 and 104 vs week 0

Mean change in Power Doppler (PD) Signal at each time point vs baseline. PD Signal ranges from 0 (low) to 84 (high)

week 4, 12, 24, 52, 76 and 104 vs week 0
mean (SD) change in Synovial Hypertrophy (SH) Total score
Tidsramme: week 4, 12, 24, 52, 76 and 104 vs week 0

Mean change in synovial hypertrophy at each time point vs baseline. Synovial hypertrophy ranges from 0 (low) to 84 (high).

week 4, 12, 24, 52, 76 and 104 vs week 0
Annualize flaire rate
Tidsramme: week 52 and week 104

Annualized flare rate in the first and second years

week 52 and week 104
Number and percentage of patients meeting the DORIS clinical remission
Tidsramme: week 12, 24, 52, 76 and 104

Number and percentage of patients meeting the DORIS clinical remission definition at each timepoints, according to:

  • Clinical SLEDAI-2K = 0;
  • PGA < 0.5;
  • Prednisolone ≤ 5 mg/day
week 12, 24, 52, 76 and 104
Number and percentage of patients with sustained DORIS remission
Tidsramme: week 104

Number and percentage of patients with sustained DORIS remission, defined as remaining in remission at or greater than 12 weeks after having met the DORIS definition

week 104
Mean (SD) HDRS (Hamilton Depression Rating Scale) total score
Tidsramme: week 12, 24, 52 and 104 vs week 0

Change in HDRS total score at different timepoints compared to T0. HDRS ranges from 0 (no depression) to 54 (severe)

week 12, 24, 52 and 104 vs week 0
Mean (SD) PROMIS Depression Short Form 8b (Patient-Reported Outcomes Measurement Information System) total score
Tidsramme: week 12, 24, 52 and 104 vs week 0

Change in PROMIS Depression Short Form 8b total score at different timepoints compared to week 0 (baseline). PROMIS raw scores ranges from 8 (no depression) to 40 (severe)

week 12, 24, 52 and 104 vs week 0

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. december 2025

Primær færdiggørelse (Anslået)

30. september 2028

Studieafslutning (Anslået)

30. september 2028

Datoer for studieregistrering

Først indsendt

19. december 2025

Først indsendt, der opfyldte QC-kriterier

8. januar 2026

Først opslået (Faktiske)

9. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner